国际移植与血液净化杂志
國際移植與血液淨化雜誌
국제이식여혈액정화잡지
INTERNATIONAL JOURNAL OF TRANSPLANTATION AND HEMOPURIFICATION
2010年
3期
27-29
,共3页
杨全会%王海军%徐海燕%黄初林%邢学忠%曲世宁%王浩%高勇%肖庆龙%孙克林
楊全會%王海軍%徐海燕%黃初林%邢學忠%麯世寧%王浩%高勇%肖慶龍%孫剋林
양전회%왕해군%서해연%황초림%형학충%곡세저%왕호%고용%초경룡%손극림
连续性静脉-静脉血液滤过%急性肾功能衰竭%腹部肿瘤%手术
連續性靜脈-靜脈血液濾過%急性腎功能衰竭%腹部腫瘤%手術
련속성정맥-정맥혈액려과%급성신공능쇠갈%복부종류%수술
Continuous venevenous hemofiltration%Acute renal failure%Abdominal cancer%Operation
目的 探讨连续性静脉-静脉血液滤过在腹部肿瘤手术后急性肾功能衰竭中应用的临床意义.方法 对31例腹部肿瘤术后急性肾功能衰竭患者采用连续性静脉-静脉血液滤过治疗,比较治疗前、后电解质、血肌酐、尿素氮以及动脉血气分析的变化.结果 31例患者中30例存活,1例死亡.存活患者经连续性静脉-静脉血液滤过后血尿素氨和肌酐均逐渐下降直至恢复正常;经连续性静脉.静脉血液滤过后4～5 h血钾可降至正常范围;酸中毒得到纠正、动脉血氧分压明显升高,尿量分别于连续性静脉-静脉血液滤过后5～20 d恢复正常,所有患者经连续性静脉-静脉血液滤过后水肿得到明显改善.结论 连续性静脉-静脉血液滤过是治疗腹部肿瘤术后急性肾功能衰竭的一种有教、方便而安全的方法.
目的 探討連續性靜脈-靜脈血液濾過在腹部腫瘤手術後急性腎功能衰竭中應用的臨床意義.方法 對31例腹部腫瘤術後急性腎功能衰竭患者採用連續性靜脈-靜脈血液濾過治療,比較治療前、後電解質、血肌酐、尿素氮以及動脈血氣分析的變化.結果 31例患者中30例存活,1例死亡.存活患者經連續性靜脈-靜脈血液濾過後血尿素氨和肌酐均逐漸下降直至恢複正常;經連續性靜脈.靜脈血液濾過後4～5 h血鉀可降至正常範圍;痠中毒得到糾正、動脈血氧分壓明顯升高,尿量分彆于連續性靜脈-靜脈血液濾過後5～20 d恢複正常,所有患者經連續性靜脈-靜脈血液濾過後水腫得到明顯改善.結論 連續性靜脈-靜脈血液濾過是治療腹部腫瘤術後急性腎功能衰竭的一種有教、方便而安全的方法.
목적 탐토련속성정맥-정맥혈액려과재복부종류수술후급성신공능쇠갈중응용적림상의의.방법 대31례복부종류술후급성신공능쇠갈환자채용련속성정맥-정맥혈액려과치료,비교치료전、후전해질、혈기항、뇨소담이급동맥혈기분석적변화.결과 31례환자중30례존활,1례사망.존활환자경련속성정맥-정맥혈액려과후혈뇨소안화기항균축점하강직지회복정상;경련속성정맥.정맥혈액려과후4～5 h혈갑가강지정상범위;산중독득도규정、동맥혈양분압명현승고,뇨량분별우련속성정맥-정맥혈액려과후5～20 d회복정상,소유환자경련속성정맥-정맥혈액려과후수종득도명현개선.결론 련속성정맥-정맥혈액려과시치료복부종류술후급성신공능쇠갈적일충유교、방편이안전적방법.
Objective To evaluate the clinical effect of continuous venovenous hemofiltration (CVVH)in acute renal failure(ARF)patients after abdominal cancer operation.Methods 31 patients with ARF after abdominal cancer operation were chosen.All cases were treated with CVVH.Electrolytes,serum creatinine,blood urea nitrogen(BUN),and blood gas analysis were detected before and after CVVH.Results 1 case out of 31 died.The levels of serum creatinine and BUN were significantly decreased after treatment.The levels of serum potassium decreased to normal level 4 to 5 hours after CVVH.In all patients acidosis was corrected,PaO2 Was improved,urine volume was regain,and edema was ameliorted.Condusion CVVH is an effective therapeutic option for ARF patients of postoperative abdominal cancer.
